Management of INR 3.28 on Warfarin
For a patient on warfarin with an INR of 3.28 who is not bleeding and has no urgent surgical needs, simply reduce the warfarin dose or omit the next dose and resume at a lower dose when the INR approaches the therapeutic range. 1
Clinical Context and Risk Assessment
An INR of 3.28 falls into the category of "above therapeutic range but ≤5" according to established guidelines. This represents a mildly elevated INR that requires intervention but not aggressive reversal. The key determinant of management is whether the patient is actively bleeding or at high risk for bleeding.
For Non-Bleeding Patients (Most Common Scenario)
The American College of Chest Physicians guidelines clearly state that when the INR is above the therapeutic range but ≤5, without clinically significant bleeding and no need for rapid reversal for surgical intervention, you should reduce the warfarin dose or omit the next dose and resume at a lower dose when the INR approaches the desired range. 1
This approach is supported by evidence showing:
- The absolute daily risk of bleeding remains low even with INRs up to 5 1
- An INR between 2.0-3.0 naturally falls to normal range over 4-5 days after stopping warfarin 1
- Watchful waiting with dose adjustment is effective for mildly elevated INRs 2, 3
Practical Dosing Strategy
When adjusting the warfarin dose for an INR of 3.28:
- Reduce the total weekly dose by 5-20% 4
- Avoid dose reductions >20% as these can lead to subtherapeutic INRs 3
- For example, if the patient takes 5 mg daily (35 mg/week), reduce to approximately 4-4.5 mg daily (28-31.5 mg/week)
Alternatively, you may omit 1-2 doses and restart at a slightly lower maintenance dose 1.
Monitoring Strategy
Recheck the INR within 1-2 weeks after dose adjustment 1. Recent evidence supports that:
- A single slightly out-of-range INR does not require immediate dose change if the patient has been previously stable 4
- However, at 3.28, a modest dose reduction is prudent to prevent further elevation
- More frequent monitoring (2-4 times per week) may be warranted initially after dose adjustment 4
When to Consider Vitamin K
Vitamin K is NOT indicated for an INR of 3.28 in a non-bleeding patient without high bleeding risk. 1
Vitamin K should be reserved for:
- INR between 5-9 in patients at increased risk of bleeding (dose: 1-2.5 mg orally) 1
- INR ≥9 without bleeding (dose: 3-5 mg orally) 1
- Any INR with active bleeding (dose varies by severity) 1
Special Considerations
High Bleeding Risk Patients
If your patient has risk factors for bleeding (age ≥65 years, history of stroke or GI bleeding, renal insufficiency, anemia, concomitant antiplatelet therapy), consider:
- More conservative dose reduction
- Shorter interval to INR recheck (within 1 week)
- Lower threshold for vitamin K administration if INR continues to rise 1
Target INR Range Matters
Ensure you know the patient's indication for warfarin:
- Most indications (atrial fibrillation, VTE, bioprosthetic valves): target INR 2.0-3.0 5
- Mechanical mitral valves or high-risk mechanical valves: target INR 2.5-3.5 5
- An INR of 3.28 may be acceptable for patients requiring higher intensity anticoagulation
Common Pitfalls to Avoid
Do not give vitamin K for an INR of 3.28 in a stable, non-bleeding patient - this can cause warfarin resistance and subtherapeutic anticoagulation 1
Do not make excessive dose reductions - reducing the dose by >20% often leads to subtherapeutic INRs 3
Do not ignore the clinical context - investigate potential causes of INR elevation (dietary changes, new medications, illness, non-adherence) 6
Do not delay follow-up INR testing - recheck within 1-2 weeks to ensure the INR returns to therapeutic range 1